Disease mechanism and novel drug therapies for atrial fibrillation
Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, affects over 3 % of adults globally, increasing risks for stroke, heart failure, and cognitive decline. Early rhythm control shows promise in improving AF prognosis, and catheter ablation remains an effective, safe option, espec...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
8. April 2025
|
| In: |
Medizinische Genetik
Year: 2025, Jahrgang: 37, Heft: 2, Pages: 147-154 |
| ISSN: | 1863-5490 |
| DOI: | 10.1515/medgen-2025-2005 |
| Online-Zugang: | Resolving-System, kostenfrei, Volltext: https://doi.org/10.1515/medgen-2025-2005 Verlag, lizenzpflichtig, Volltext: https://www.degruyterbrill.com/document/doi/10.1515/medgen-2025-2005/html 
|
| Verfasserangaben: | Felix Wiedmann, Constanze Schmidt |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1934918253 | ||
| 003 | DE-627 | ||
| 005 | 20250828112422.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250828s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/medgen-2025-2005 |2 doi | |
| 035 | |a (DE-627)1934918253 | ||
| 035 | |a (DE-599)KXP1934918253 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wiedmann, Felix Tobias |d 1987- |e VerfasserIn |0 (DE-588)1055852441 |0 (DE-627)792733479 |0 (DE-576)411904159 |4 aut | |
| 245 | 1 | 0 | |a Disease mechanism and novel drug therapies for atrial fibrillation |c Felix Wiedmann, Constanze Schmidt |
| 264 | 1 | |c 8. April 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.08.2025 | ||
| 520 | |a Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, affects over 3 % of adults globally, increasing risks for stroke, heart failure, and cognitive decline. Early rhythm control shows promise in improving AF prognosis, and catheter ablation remains an effective, safe option, especially for paroxysmal AF. However, high recurrence rates with antiarrhythmic drugs and ablation persist, particularly in cases of persistent AF. Emerging research on molecular mechanisms has led to innovative therapeutic strategies targeting these pathways, offering hope for more effective AF management. This review explores recent insights into the complex pathophysiology of AF, with a particular focus on ion channel dysfunction, calcium mishandling, oxidative stress, and fibrosis. It further considers how these factors will inspire new therapeutic options. | ||
| 650 | 4 | |a Antiarrhythmic therapy | |
| 650 | 4 | |a Atrial fibrillation | |
| 650 | 4 | |a cellular electrophysiology | |
| 650 | 4 | |a Molecular pathophysiology | |
| 650 | 4 | |a TASK-1 potassium channels | |
| 700 | 1 | |a Schmidt, Constanze |e VerfasserIn |0 (DE-588)1055852174 |0 (DE-627)792733142 |0 (DE-576)411903721 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medizinische Genetik |d Berlin : de Gruyter, 1998 |g 37(2025), 2, Seite 147-154 |h Online-Ressource |w (DE-627)39761571X |w (DE-600)2163157-8 |w (DE-576)265030536 |x 1863-5490 |7 nnas |a Disease mechanism and novel drug therapies for atrial fibrillation |
| 773 | 1 | 8 | |g volume:37 |g year:2025 |g number:2 |g pages:147-154 |g extent:8 |a Disease mechanism and novel drug therapies for atrial fibrillation |
| 856 | 4 | 0 | |u https://doi.org/10.1515/medgen-2025-2005 |x Resolving-System |x Verlag |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.degruyterbrill.com/document/doi/10.1515/medgen-2025-2005/html |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250828 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1055852174 |a Schmidt, Constanze |m 1055852174:Schmidt, Constanze |d 910000 |d 910100 |d 50000 |e 910000PS1055852174 |e 910100PS1055852174 |e 50000PS1055852174 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 2 |y j | ||
| 998 | |g 1055852441 |a Wiedmann, Felix Tobias |m 1055852441:Wiedmann, Felix Tobias |d 910000 |d 910100 |e 910000PW1055852441 |e 910100PW1055852441 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1934918253 |e 4765120481 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"id":{"issn":["1863-5490"],"zdb":["2163157-8"],"eki":["39761571X"]},"name":{"displayForm":["Berufsverband Medizinische Genetik e.V."]},"language":["ger"],"recId":"39761571X","pubHistory":["Nachgewiesen 10.1998 -"],"origin":[{"publisherPlace":"Berlin ; Berlin ; Heidelberg","dateIssuedDisp":"1998-","publisher":"de Gruyter ; Springer","dateIssuedKey":"1998"}],"note":["Gesehen am 12.04.2023"],"disp":"Disease mechanism and novel drug therapies for atrial fibrillationMedizinische Genetik","physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Medizinische Genetik","title":"Medizinische Genetik"}],"part":{"volume":"37","extent":"8","issue":"2","year":"2025","pages":"147-154","text":"37(2025), 2, Seite 147-154"},"type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"display":"Berufsverband Medizinische Genetik","role":"isb"}]}],"recId":"1934918253","origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"8. April 2025"}],"note":["Gesehen am 28.08.2025"],"id":{"doi":["10.1515/medgen-2025-2005"],"eki":["1934918253"]},"physDesc":[{"noteIll":"Illustrationen","extent":"8 S."}],"title":[{"title_sort":"Disease mechanism and novel drug therapies for atrial fibrillation","title":"Disease mechanism and novel drug therapies for atrial fibrillation"}],"person":[{"family":"Wiedmann","role":"aut","display":"Wiedmann, Felix Tobias","given":"Felix Tobias"},{"role":"aut","display":"Schmidt, Constanze","given":"Constanze","family":"Schmidt"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"name":{"displayForm":["Felix Wiedmann, Constanze Schmidt"]}} | ||
| SRT | |a WIEDMANNFEDISEASEMEC8202 | ||